About Us

Company Origins

Founded in February 2013 as MicroDevice Engineering LLC and incorporated in 2016, MDE is working to create a blood typing and hematocrit device based on the research of the Medical micro-Device Engineering Research Lab (M.D.-ERL) at Michigan Technological University. MDE received funding from the National Science Foundation's Small Business Technology Transfer program, with a Phase I grant in 2014. MDE is the first company to simultaneously receive both the NSF STTR and the NSF Partnership for Innovation: Accelerating Innovation Research-Technology Transfer (PFI:AIR-TT) grant. In September 2016, MDE was awarded the STTR Phase II grant, which will allow continued development and the first deployment of the device.

Company Description

MDE’s Mission is to provide rapid, accurate diagnostic point-of-care devices that optimize testing and lead to better outcomes for patients. Our first device simplifies blood typing and hematocrit measurement during blood collection.

MDE’s Technological Impact

MDE's patent-pending technology can detect molecular-level differences on cell surfaces in just minutes, without the use of reagents. The technology can be engineered to be selective, and is sensitive enough to identify cells with different surface biomarkers for cell recognition (i.e., STEM cells, cancer cells, etc.). This fills a broad need in diagnostics health care, and has the potential to be a significant advance in platform technology.

MDE’s Societal Impact

The U.S. health care industry is under significant pressure to improve quality and safety at lower costs. Blood products (red cells, plasma, and platelets) are a critical supply chain component within the U.S. health care delivery system. Delivering the proper blood product quickly can literally save lives. Studies show that fresher blood products result in better patient outcomes after trauma, cancer or surgical procedure. Our blood typing and hematocrit device has the potential to usher in improvements in blood collection and processing that can reduce complications and health care costs.

MDE’s blood typing and hematocrit device will help transform the collection process to improve supply/demand matching between blood donation clinics and hospitals/clinics by increasing the usage of apheresis donation. Apheresis allows blood to be taken from the donor, one or more blood components removed, and the remaining components returned to the donor. This allows the donation clinic to extract the optimal components of donor blood at each donation, which ensures only those components that can be readily used are extracted. The addition of hematocrit measurement means that donation clinics can rely on one device to simultaneously report both blood type and hematocrit levels, again reducing costs and simplifying the donation process.